AstraZeneca reported a half in which the story is exactly the one management wanted to tell, and exactly the one the market has been arguing about for two years. Total Revenue of $30.7 billion in the first six months of 2026 rose 9% on a reported basis and 6% at constant exchange rates, Core operating profit and Core EPS each grew 11% at CER, and a slate of eight first approvals and six positive Phase III readouts pushed the pipeline to 30 launches in major regions since the prior results. The bear case lives in two places, both visible on the same page. Farxiga - the franchise that funded the last decade of growth - fell 5% in the half on US loss of exclusivity, dragging the Cardiovascular-Renal-Metabolic franchise down 8% reported and 12% CER. And the Q2 reported operating profit of $3,164 million fell 10% on a 6% reported revenue increase, because R&D rose 14%, SG&A rose 16%, and intangible-asset impairment of $345 million landed in the quarter. The market is being asked to pay roughly 14–16x forward earnings for a company whose growth is concentrated in Oncology and Rare Disease while a $4 billion Farxiga franchise starts to compress. The open question is whether the twelve high-value readouts management has scheduled over the next 18 months can fill the Farxiga gap fast enough to justify the multiple, or whether the second half has to be visibly stronger to hold it.